Cargando…
Comment on: “Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Mode”
Autor principal: | Rascati, Karen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629126/ https://www.ncbi.nlm.nih.gov/pubmed/28528515 http://dx.doi.org/10.1007/s40268-017-0185-9 |
Ejemplares similares
-
Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Model
por: Brunelli, Steven M., et al.
Publicado: (2017) -
Ferric Citrate Hydrate as a Phosphate Binder and Risk of Aluminum Toxicity
por: Gupta, Ajay
Publicado: (2014) -
Randomized Study of Tenapanor Added to Phosphate Binders for Patients With Refractory Hyperphosphatemia
por: Nitta, Kosaku, et al.
Publicado: (2023) -
Ferric citrate for the treatment of hyperphosphatemia and anemia in patients with chronic kidney disease: a meta-analysis of randomized clinical trials
por: Li, Li, et al.
Publicado: (2022) -
Comparative Gut Microbiome Differences between Ferric Citrate and Calcium Carbonate Phosphate Binders in Patients with End-Stage Kidney Disease
por: Wu, Ping-Hsun, et al.
Publicado: (2020)